Bavanthi Balakrishnar
Overview
Explore the profile of Bavanthi Balakrishnar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
234
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Azad A, Bressel M, Tan H, Voskoboynik M, Suder A, Weickhardt A, et al.
Lancet Oncol
. 2024 Sep;
25(10):1267-1276.
PMID: 39293461
Background: Lutetium-177 [Lu]Lu-prostate-specific membrane antigen (PSMA)-617 improves survival and quality of life in patients with metastatic castration-resistant prostate cancer, but whether it confers a benefit in hormone-sensitive disease is unknown....
2.
Liang R, Adams D, Roncolato F, Asghari R, Descallar J, Pal A, et al.
Clin Genitourin Cancer
. 2024 May;
22(4):102116.
PMID: 38810324
Purpose: Adherence to active surveillance in patients with stage 1 testicular cancers may be influenced by factors affecting capacity and motivation to attend appointments. The aims of this study were...
3.
Hong J, Nindra U, Nguyen R, Gassner P, Balakrishnar B, Rutland T
Case Rep Oncol
. 2023 Jan;
15(3):1055-1062.
PMID: 36605230
Prostate adenocarcinoma with testicular metastasis is rare, present in up to 4% of autopsy diagnoses, and presents symptomatically in less than 0.5% of cases. We report an unusual case of...
4.
Khan T, Lock J, Ma Y, Harman D, de Souza P, Chua W, et al.
Sci Rep
. 2022 Sep;
12(1):16159.
PMID: 36171234
Androgen receptor variant 7 (AR-V7) is an important biomarker to guide treatment options for castration-resistant prostate cancer (CRPC) patients. Its detectability in circulating tumour cells (CTCs) opens non-invasive diagnostic avenues....
5.
Nindra U, Hong J, Balakrishnar B, Pal A, Chua W
Clin Genitourin Cancer
. 2022 Aug;
21(1):183-193.
PMID: 35927195
There is emerging evidence for the use of poly (ADP-ribose) polymerase inhibitors (PARPi) in patients with mCRPC with patients harboring germline or somatic mutations deriving clinical benefit. However, the toxicity...
6.
Young F, Becker T, Nimir M, Opperman T, Chua W, Balakrishnar B, et al.
J Clin Med
. 2022 Jan;
11(1).
PMID: 35011998
Androgen Receptor (AR) alterations (amplification, point mutations, and splice variants) are master players in metastatic castration resistant prostate cancer (CRPC) progression and central therapeutic targets for patient management. Here, we...
7.
Arasaratnam M, Balakrishnar B, Crumbaker M, Turner S, Hayden A, Brooks A, et al.
Asia Pac J Clin Oncol
. 2021 Jun;
18(2):e23-e31.
PMID: 34152083
Aim: To evaluate disease presentation, treatment practices, and outcomes of patients with germ cell tumor (GCT) treated in a high-volume cancer center in Australia. Methods: This is a retrospective analysis...
8.
Po J, Ma Y, Luk A, Lynch D, Balakrishnar B, Brungs D, et al.
Methods Mol Biol
. 2021 Mar;
2265:277-286.
PMID: 33704722
Molecular testing of tumor biopsies allows for the identification of the key mutations driving a patient's cancer. However, this is limited to singular nodes and may not accurately reflect cancer...
9.
Po J, Ma Y, Balakrishnar B, Brungs D, Azimi F, Cooper A, et al.
Methods Mol Biol
. 2021 Mar;
2265:223-233.
PMID: 33704718
The advent of personalized medicines targeting cell signaling pathways has radically improved melanoma patient outcomes. More recently, immune-modulating therapies disrupting the PD-1/PD-L1 axis have become a powerful tool in the...
10.
Lee C, Low S, Maldonado R, Fox P, Balakrishnar B, Coulter S, et al.
Breast
. 2020 Nov;
54:229-234.
PMID: 33161337
Introduction: CYP2D6 protein activity can be inferred from the ratio of N-desmethyl-tamoxifen (NDMT) to endoxifen (E). CYP2D6 polymorphisms are common and can affect CYP2D6 protein activity and E level. Some...